drugset / Trial / NCT05374603
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, interventional, multiple-center, exploratory Phase II study sponsored by AstraZeneca Investment(China)Co., LTD. to evaluate the efficacy and safety of Savolitinib combine with Durvalumab in Chinese EGFR wild-type locally advanced or metastatic NSCLC patients with MET alteration.
Timeline
- Start
- 2022-11-15
- Primary completion
- 2027-01-18
- Completion
- 2027-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Savolitinib | Small molecule | 400 mg | Oral |
| Subject | Savolitinib | Small molecule | 600 mg | Oral |